Completed OBSERVATIONAL NCT00499187

Fanconi Syndrome Due to ARVs in HIV-Infected Persons

A Preliminary Evaluation of Fanconi Syndrome Due to Antiretroviral Therapies in HIV-Infected Persons

Sponsor: Gilead Sciences

Conditions Fanconi Syndrome HIV Infections Kidney Disease Renal Impairment

Interventions Blood Draws

Updated 11 times since 2017 Last updated: Mar 14, 2014 Started: Sep 30, 2007 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00499187, this observational or N/A phase trial focuses on Fanconi Syndrome and HIV Infections and remains completed. Sponsored by Gilead Sciences, it has been updated 11 times since 2007, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 6 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: PHASE4 → None
Aug 2017 — Apr 2018 [monthly]

Completed PHASE4
Feb 2017 — Aug 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences

Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Cleveland, United States , Denver, United States , Detroit, United States , Houston, United States , Indianapolis, United States , Los Angeles, United States , Miami, United States , Montreal, Canada and 3 more locations